CD38 and B-cell chronic lymphocytic leukemia: Moreover, in the relapsed group, expression of NGAL-R/CD38 in CLL cells (84%/85% at 24 months after treatment) from patient P44 was markedly higher than in leukemic cells from patients P39 (20%/25% at 48 months after treatment) and P43 (26%/22% at 72 months after treatment).